Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
maplirpacept + rituximab
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This is a combination therapy of **maplirpacept** (an engineered CD47 decoy receptor that blocks the "don't eat me" signal, thereby promoting phagocytosis by macrophages) and **rituximab** (a chimeric monoclonal antibody against CD20, widely used to target B-cells in hematologic cancers, especially non-Hodgkin lymphoma). Both drugs exert anticancer effects via distinct, non-overlapping immunological mechanisms; maplirpacept enhances macrophage-mediated clearance of tumor cells while rituximab promotes immune effector functions such as antibody-dependent cellular cytotoxicity. Together, they may act synergistically, and preclinical data suggest enhanced antitumor activity over single-agent therapy in diffuse large B-cell lymphoma (DLBCL) and possibly other hematological malignancies[1].
- Brand names
- RituxanRiabniRuxienceTruximaMabThera
- Other names
- TTI-621 plus rituximabTTI621 plus rituximabTTI 621 plus rituximab
02
Targets
CD47 (Cluster of Differentiation 47)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on maplirpacept + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on maplirpacept + rituximab.